Shares of MiniMed Group surged 10.1% to $22.30 on September 1, defying a softer broader market, after the insulin-pump maker posted first-quarter fiscal 2027 results that beat expectations and nudged its full-year growth forecast higher. For investors, the question is whether this momentum reflects a durable shift in the business or a one-quarter sugar rush.
$843 Million in Revenue Shows the Core Business Is Accelerating MiniMed Beats Estimates and Raises Guidance on Pump Surge — But Can a Still-Unprofitable Spinoff Justify Its Rally?
Shares of MiniMed Group vaulted 10.1% to $22.30 on September 1, blowing past the analyst consensus price target of $21, after the recently spun-off insulin-pump maker posted a first quarter that exceeded its own expectations and lifted full-year guidance. The move now prices the stock above every major Wall Street target — raising the stakes for the quarters ahead.
A New Pump Is Winning Over Doctors and Patients
U.S. revenue growth hit 13.1%, fueled by more than 20% growth in new pumps sold and a 24% jump in new prescribers. The catalyst: the launch of MiniMed's redesigned, smartphone-controlled Flex insulin pump, which began shipping in late June and contributed about five weeks of shipments during the quarter. That kind of doctor adoption rate matters because each new prescriber creates a stream of recurring revenue from sensors and supplies. The rate at which pump users also buy MiniMed's glucose sensors climbed to 69%, up five percentage points year-over-year — a sign the company is selling more products per patient.
The Headline Growth Rate Needs an Asterisk
Organic revenue grew 15.8% to $843 million, but an extra week in the fiscal calendar contributed an estimated four to six percentage points of that growth.
Stripping that out, revenue grew at a low-double-digit rate — still a meaningful acceleration from 8.7% the prior quarter. Investors should benchmark future quarters against this adjusted figure, not the splashy headline number.
Guidance Goes Up, but Profits Remain Elusive
Management raised the fiscal 2027 organic revenue growth outlook to ~10.5% while reaffirming an adjusted EBITDA margin target of 16%. However, Q1 adjusted EBITDA (a rough proxy for operating cash flow before certain costs) was just $83 million at a 9.9% margin , well below the annual target — meaning margins must ramp sharply in coming quarters. The company posted a $317 million net loss in fiscal 2026 , so the path from top-line momentum to actual profitability is still unproven.
The Pipeline Could Extend the Runway — or Distract from Margins
MiniMed is advancing four pipeline programs, including a next-generation patch pump and a fully automated dosing algorithm that requires no manual mealtime input, both expected in calendar 2027. If cleared, these products could widen MiniMed's addressable market. But continued R&D and separation costs from parent Medtronic — which still owns roughly 90% of shares — will pressure cash flow in the near term.